HCG announces new standard-of-care for cancer treatment in India

150 150 Strand Life Sciences
  • HCG partners with Strand Life Sciences to integrate genomics as a ‘standard of care’ in cancer treatment and risk prediction.
  • Cancer treatment adapted for Indian genomic variations.
  • Affordable tests that improve precision treatment decisions and clinical outcomes in cancer care.

      HealthCare Global (HCG) Enterprises Ltd, The Specialists in Cancer Care, creates a new benchmark in cancer care by making genomics-based diagnostics, a ‘standard-of-care’ for cancer treatment in India. These diagnostic tests will support physicians, and their patients with the most accurate and advanced tumor profiling of large number genes for “actionable” mutations. The information about these mutations helps to identify targeted therapies and treatment choices early in the course of cancer care.

Triesta Sciences, unit of HCG, is partnering for cancer genomics with Strand Life Sciences, a pioneer in the field of clinical genomics, to setup a new center for genomics called ‘Strand-Triesta Center for Cancer Genomics’ (Strand-Triesta) with the aim of making genomics based diagnostics effective, accessible and affordable. Strand-Triesta will enable the world’s largest adoption of genomics-based tumor profiling for HCG patients. HCG will lead the way by adopting the Strand-Triesta advanced cancer diagnostics as a new standard that defines the future of cancer care. The partnership will also bring to bear the respective strengths of both organizations: Triesta Sciences and Strand – a global pioneer in new generation clinical diagnostics.

There is a rising healthcare burden of cancer in India with current estimates of a million cases of cancer being reported each year with mortality close to 500,000. It is expected that the number of incidences of cancer will rise five-fold by 2025 thereby increasing the healthcare burden. Against this backdrop, the new ‘standard-of-care’ would help meet the growing cancer ‘epidemic’ which the country is combating. The new standard-of-care aims to achieve new frontiers in medicine by introducing concepts like ‘bench to bedside vision’ wherein physicians and patients will have ready access to advanced innovation and discovery right at the bedside.

Sequencing of tumor using next generation sequencing (NGS)  technologies, and thorough analysis of individual patient’s DNA variations will help physicians go beyond a ‘one size fits all’ model of cancer therapy. Such personalized approaches will improve response rates and effectiveness of targeted, chemo- and radiation therapies. Further, genomic tests can detect hereditary risk in family members of cancer patients.

Dr. B S Ajaikumar, Founder, Chairman, HCG Enterprise, on this occasion, said “HCG’s has been in the forefront in redefining cancer care. We will now incorporate genomic testing which is personalized and will be the future of cancer care. This will help oncologists in clinical decisions and help our patients receive targeted individualized therapies that will improve diagnosis and prognosis of cancer. We are pleased to partner with Strand Life Sciences, which through its expertise will offer comprehensive genomic tests for cancer and other germline conditions at affordable rates to our patients. Through this partnership between Triesta Sciences and Strand Life Sciences we hope to enhance the work done by multi- disciplinary team of eminent and established oncologists. With this HCG joins a select group of advanced cancer care centers.”

A new generation healthcare innovation company, Strand, has a distinguished team of over 200 scientists and researchers working to create novel solutions in genomics and personalized medicine. Strand has brought together the best-in-class computational and biological sciences to bring precision genomics to advanced clinical solutions for healthcare institutions. Strand Life Sciences has developed cost effective, next generation genomic tests, through a decade of R&D innovations. Further research on molecular profiles of patients will help establish new targets for the development of targeted cancer drugs, specifically for the Indian population.

Talking about this partnership, Dr. Vijay Chandru, Chairman  & CEO, Strand Life Sciences said, “Strand is committed to expanding clinical genomics as a new paradigm for clinical decision support. The coming together of HCG, Triesta and Strand will result in achieving a scale of adoption of genomic testing, which is unprecedented even in the West. This scale enables affordability, but more importantly, the more cancer genomes we profile, the deeper the insights about cancer we gain. Deeper insights lead to informed decisions in cancer care. ”

About HCG

HealthCare Global Enterprises Ltd, the specialist in cancer care has its headquarters in Bangalore, India and is known to be the only dedicated cancer care network with quality care across 27 centers.

Being a leader in the area of cancer care two years in a row has given HealthCare Global Enterprises (HCG) the exposure and expertise to provide hope to 100,000 new patients every year. After having established itself as a center for advanced, complicated and recurrent cancers, today it is known as the specialist in the field – nationally and internationally. 2011 and 2012 were the years when our work was given global recognition with the ‘Leader in Oncology Two Years in a Row’ excellence in Indian Health Care Awards.

For more information, visit www.hcgoncology.com

About Strand Life Sciences

Strand Life Sciences – is a new generation healthcare innovation company. Strand’s entry into healthcare was through products and services that combine advanced visualization, systems modeling, and scientific insights for enabling basic biological research. Over 2000 research laboratories worldwide (about 30% of global market share) are licensees of Strand’s technology products as are several leading pharmaceutical and biotechnology companies. Strand has set up three clinical and research laboratories in Bangalore, enabled with the cutting-edge Next Generation Sequencing (NGS) technologies. Strand is a portfolio company of Biomark Capital Partners, a San Francisco based global fund for health and life sciences. By enabling DNA sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing individualized medicine to the world.

For more information, visit www.strandls.com or follow us on twitter @StrandLife

About Triesta Sciences

Triesta Sciences, a unit of HEALTH CARE GLOBAL (HCG) Enterprises Limited, is the state-of-the-art one point solution for oncology diagnostics, biomarker and translational research, laboratory services and clinical research services. Based out of Bangalore, Triesta Sciences is an integration of laboratory services, R&D and clinical research with a focus to on innovation, quality and accuracy for better diagnosis and prognosis of cancer.

Triesta Reference laboratory is the largest network of CAP and NABL accredited high end oncology diagnostic laboratory service provider in the country offering a comprehensive range of routine to highly specialized diagnostic tests for hospitals, medical institutions within India and overseas .

The Research and Development is intellectual property driven, and serves to create an accelerated bridge between basic research and clinical implementation through high quality translational research to understand disease pathogenesis, translate such knowledge into improvements in patient care and set new paradigm in personalized medicine era through biospecimen banking.

For more information, visit www.triesta.com

Media Contact:
Ajay Muliyil/ Preeti Goswami
Ogilvy Public Relation
Mob: 99001 61311/ 95356 78825


Strand Life Sciences

All stories by: Strand Life Sciences